Why Cell and Gene Therapy Data Sharing Is Becoming the Industry’s Biggest Bottleneck
Industry leaders argue that the scientific breakthroughs behind cell and gene therapies are no longer the main barrier. Instead, the core challenge now sits in how stakeholders share, structure, and interpret data across the entire ecosystem. Audrey Greenberg, CEO of AG Capital Advisors, emphasized that commercialization drives most decisions today. She pointed to pricing pressure, approval speed, and manufacturing cost as tightly connected forces that define whether therapies can reach patients at scale.
Manufacturing Limits in Cell and Gene Therapy Are Slowing Down Global Scale-Up
Manufacturing continues to limit the scalability of CGT programs. Although production science has advanced, many organizations still rely on paper-based batch records. Industry experts warn that this approach slows operations and increases risk in complex workflows. Jason Foster, CEO of Oribiotech, highlighted that paper systems cannot support modern advanced therapies. As a result, the sector faces growing pressure to digitize manufacturing and remove fragmented documentation processes.
How Regulatory Pressure Is Reshaping Cell and Gene Therapy Development Pathways
Regulatory expectations are also evolving rapidly. The FDA and its Center for Biologics Evaluation and Research (CBER) have begun emphasizing structured data sharing and early scientific engagement. Following a public listening session in 2025, the FDA issued draft guidance encouraging sponsors to explore data leveraging opportunities. This shift signals a broader move toward evidence-driven flexibility in regulatory decision-making, especially for advanced therapies.
The Commercial Viability Crisis Behind Cell and Gene Therapy Programs
Commercial reality continues to challenge the sustainability of CGT companies. Despite scientific success, several high-profile companies have struggled financially after reaching the market. Bluebird bio is often cited as a key example, where strong innovation did not translate into long-term financial stability. Industry analysts link these outcomes to manufacturing inefficiencies, pricing constraints, and insufficient data infrastructure across the value chain.
What COVID-19 Taught the Pharma Industry About Fast-Track Collaboration and Data Sharing
Experts frequently compare the current CGT landscape with the COVID-19 pandemic response. During that period, unprecedented collaboration between governments, regulators, and industry players accelerated vaccine development. Programs such as ACTIV demonstrated how shared data ecosystems can significantly reduce timelines while maintaining regulatory rigor. Stakeholders now question whether a similar collaborative model can be applied to cell and gene therapy to improve access and efficiency.
This article highlights the urgent need for integrated digital systems to replace fragmented data and paper-based batch records in CGT manufacturing. It reflects a clear industry shift toward scalable and compliant GMP digital operations.
If your organization is facing similar challenges, our Digital Solutions for GMP-Regulated Operations can help build connected and compliant digital workflows across the GMP lifecycle.
Source: Biospace.Com